Hookipa Pharma Inc (HOOK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hookipa Pharma Inc (HOOK) has a cash flow conversion efficiency ratio of -0.249x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.13 Million) by net assets ($28.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HOOK net asset quality score to measure how much of total assets are equity-financed.
Hookipa Pharma Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Hookipa Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Hookipa Pharma Inc (HOOK) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Hookipa Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hookipa Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ecomiam SA
PA:ALECO
|
-0.357x |
|
Biomaxima
WAR:BMX
|
0.022x |
|
XINYUAN REAL ESTATE ADR20
F:3XR
|
N/A |
|
TwentyFour Income Fund Ltd
LSE:TFIF
|
0.015x |
|
TAO Synergies Inc.
NASDAQ:TAOX
|
-0.072x |
|
TS Corp Preference Shares
KO:001795
|
0.047x |
|
Biovie Inc
NASDAQ:BIVI
|
-0.477x |
|
Advanced Packaging Tech (Malaysia)
KLSE:9148
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Hookipa Pharma Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Hookipa Pharma Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Hookipa Pharma Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $32.52 Million | $-11.50 Million | -0.354x | +76.47% |
| 2024-12-31 | $51.21 Million | $-76.98 Million | -1.503x | -134.79% |
| 2023-12-31 | $89.86 Million | $-57.52 Million | -0.640x | -228.19% |
| 2022-12-31 | $102.52 Million | $-20.00 Million | -0.195x | +73.53% |
| 2021-12-31 | $89.59 Million | $-66.02 Million | -0.737x | -192.43% |
| 2020-12-31 | $156.12 Million | $-39.34 Million | -0.252x | +28.81% |
| 2019-12-31 | $117.90 Million | $-41.73 Million | -0.354x | -4.78% |
| 2018-12-31 | $44.40 Million | $-15.00 Million | -0.338x | -220.95% |
| 2017-12-31 | $-42.66 Million | $-11.91 Million | 0.279x | -- |
About Hookipa Pharma Inc
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancer… Read more